Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays / Evaluación de tres inmunoensayos comercializados de inmunoglobulina G para el diagnóstico del virus del chikungunya
Rev Panam Salud Publica
; 41, jun. 2017
Article
in English
| PAHO-IRIS
| ID: phr-34100
Responsible library:
US1.1
ABSTRACT
The emergence of chikungunya virus in the Americas means the affected population is at risk of developing severe, chronic, rheumatologic disease, even months after acute infection. Accurate diagnostic methods for past infections are essential for differential diagnosis and consequence management. This study evaluated three commercially-available chikungunya Immunoglobulin G immunoassays by comparing them to an in-house Enzyme-Linked ImmunoSorbent Assay conducted by the Centers for Disease Control and Prevention (Atlanta, Georgia, United States). Results showed sensitivity and specificity values ranging from 92.8% – 100% and 81.8% – 90.9%, respectively, with a significant number of false-positives ranging from 12.5% – 22%. These findings demonstrate the importance of evaluating commercial kits, especially regarding emerging infectious diseases whose medium and long-term impact on the population is unclear.
Full text:
Available
Collection:
Databases of international organizations
Health context:
SDG3 - Health and Well-Being
/
Neglected Diseases
Health problem:
Target 3.3: End transmission of communicable diseases
/
Chikungunya Fever
/
Neglected Diseases
Database:
PAHO-IRIS
Main subject:
Reagent Kits, Diagnostic
/
Americas
/
Immunoassay
/
Chikungunya virus
/
Fluorescence Polarization Immunoassay
/
Immunoenzyme Techniques
/
Caribbean Region
Type of study:
Diagnostic study
Language:
English
Year:
2017
Document type:
Article